Table 3.
Independent predictors of disease progression among adult COVID-19 patients included in the study, grouped by progression occurence
| Disease progression (n = 27) | No disease progression (n = 123) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |||
| Age | 74.0 ± 23.1 (41.0–91.0) | 66.0 ± 12.9 (20.0–93.0) | 1.04 (1.01–10.9) | 0.01 | – | |
| Male gender | 12 (44.0) | 64 (52.0) | 0.74 (0.32–1.72) | 0.47 | ||
| Time from disease onset to antiviral therapy | 3.3 ± 7.8 (1–34) | 3.5 ± 7.8 (1–34) | 0.91 (0.81–1.01) | 0.07* | n.a | |
| Chronic heart disease | 18 (66.7) | 34 (27.6) | 5.81 (2.32–14.70) | < 0.01 | 4.27 (1.41–12.98) | 0.01 |
| Diabetes mellitus | 10 (37.0) | 23 (18.7) | 2.69 (1.08–6.71) | 0.03 | – | |
| Need for oxygen supportation | 16 (59.3) | 32 (26.0) | 4.13 (1.74–9.80) | 0.01 | – | |
| Severe COVID-19 | 26 (96.3) | 50 (27.0) | 38.5 (5.0–333.30) | < 0.01 | 21.28 (2.32–200.0) | < 0.01 |
| Any supportive therapy needed | 26 (96.3) | 63 (51.2) | 5.10 (1.82–14.30) | < 0.01 | – | |
| Any antibacterial therapy needed | 22 (81.5) | 86 (69.9) | 1.89 (0.67–5.37) | 0.23 | ||
| Any antiviral therapy needed | 25 (92.6) | 114 (92.7) | 1.01 (0.21–4.98) | 0.98 | ||
| Treatment with favipiravir | 17 (63.0) | 58 (47.2) | 1.91 (0.81–4.48) | 0.14 | – | |
n.a., not applicable
*The parameter was not included in the final model as co-linearity was not proven by the Box-Tidwell test with Bonferroni’s post hoc correction (p < 0.01)